<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35500936</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2575-1077</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Life science alliance</Title>
          <ISOAbbreviation>Life Sci Alliance</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exploring YAP1-centered networks linking dysfunctional CFTR to epithelial-mesenchymal transition.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e202101326</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.26508/lsa.202101326</ELocationID>
        <Abstract>
          <AbstractText>Mutations in the CFTR anion channel cause cystic fibrosis (CF) and have also been related to higher cancer incidence. Previously we proposed that this is linked to an emerging role of functional CFTR in protecting against epithelial-mesenchymal transition (EMT). However, the pathways bridging dysfunctional CFTR to EMT remain elusive. Here, we applied systems biology to address this question. Our data show that YAP1 is aberrantly active in the presence of mutant CFTR, interacting with F508del, but not with wt-CFTR, and that YAP1 knockdown rescues F508del-CFTR processing and function. Subsequent analysis of YAP1 interactors and roles in cells expressing either wt- or F508del-CFTR reveal that YAP1 is an important mediator of the fibrotic/EMT processes in CF. Alongside, five main pathways emerge here as key in linking mutant CFTR to EMT, namely, (1) the Hippo pathway; (2) the Wnt pathway; (3) the TGFβ pathway; (4) the p53 pathway; and (5) MYC signaling. Several potential hub proteins which mediate the crosstalk among these pathways were also identified, appearing as potential therapeutic targets for both CF and cancer.</AbstractText>
          <CopyrightInformation>© 2022 Quaresma et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Quaresma</LastName>
            <ForeName>Margarida C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botelho</LastName>
            <ForeName>Hugo M</ForeName>
            <Initials>HM</Initials>
            <Identifier Source="ORCID">0000-0002-4208-1086</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pankonien</LastName>
            <ForeName>Ines</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4622-7521</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodrigues</LastName>
            <ForeName>Cláudia S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinto</LastName>
            <ForeName>Madalena C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-9045-269X</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Costa</LastName>
            <ForeName>Pau R</ForeName>
            <Initials>PR</Initials>
            <Identifier Source="ORCID">0000-0003-3527-5381</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duarte</LastName>
            <ForeName>Aires</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amaral</LastName>
            <ForeName>Margarida D</ForeName>
            <Initials>MD</Initials>
            <Identifier Source="ORCID">0000-0002-0828-8630</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal mdamaral@fc.ul.pt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Life Sci Alliance</MedlineTA>
        <NlmUniqueID>101728869</NlmUniqueID>
        <ISSNLinking>2575-1077</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505032">CFTR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126880-72-6</RegistryNumber>
          <NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019005" MajorTopicYN="Y">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016271" MajorTopicYN="N">Proto-Oncogene Proteins c-myc</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>20</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35500936</ArticleId>
        <ArticleId IdType="pmc">PMC9060002</ArticleId>
        <ArticleId IdType="doi">10.26508/lsa.202101326</ArticleId>
        <ArticleId IdType="pii">5/9/e202101326</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science
245: 1066–1073. 10.1126/science.2475911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2475911</ArticleId>
            <ArticleId IdType="pubmed">2475911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet
373: 1891–1904. 10.1016/S0140-6736(09)60327-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)60327-5</ArticleId>
            <ArticleId IdType="pubmed">19403164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Boeck K, Amaral MD (2016) Progress in therapies for cystic fibrosis. Lancet Respir Med
4: 662–674. 10.1016/S2213-2600(16)00023-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(16)00023-0</ArticleId>
            <ArticleId IdType="pubmed">27053340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell SC, De Boeck K, Amaral MD (2015) New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol Ther
145: 19–34. 10.1016/j.pharmthera.2014.06.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2014.06.005</ArticleId>
            <ArticleId IdType="pubmed">24932877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB (2013) Cancer risk in cystic fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst
105: 122–129. 10.1093/jnci/djs481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djs481</ArticleId>
            <ArticleId IdType="pubmed">23178438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, Welsh MJ, Zabner J, Polgreen PM (2020) Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A
117: 1621–1627. 10.1073/pnas.1914912117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1914912117</ArticleId>
            <ArticleId IdType="pmc">PMC6983448</ArticleId>
            <ArticleId IdType="pubmed">31882447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y, Fok KL, Zhang XH, Sun TT, Tsang LL, et al.  (2013) Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta
1833: 2961–2969. 10.1016/j.bbamcr.2013.07.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2013.07.021</ArticleId>
            <ArticleId IdType="pubmed">23916755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu Z, Chen Q, Zhang JT, Jiang X, Xia Y, Chan HC (2016) CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis. Oncotarget
7: 76955–76965. 10.18632/oncotarget.12762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12762</ArticleId>
            <ArticleId IdType="pmc">PMC5363562</ArticleId>
            <ArticleId IdType="pubmed">27769067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Zhang JT, Jiang X, Shi X, Shen J, Feng F, Chen J, Liu G, He P, Jiang J, et al.  (2015) The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer. Int J Oncol
46: 2107–2115. 10.3892/ijo.2015.2921</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2015.2921</ArticleId>
            <ArticleId IdType="pubmed">25760446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun TT, Wang Y, Cheng H, Xiao HZ, Xiang JJ, Zhang JT, Yu SB, Martin TA, Ye L, Tsang LL, et al.  (2014) Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochim Biophys Acta
1843: 618–628. 10.1016/j.bbamcr.2013.12.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2013.12.013</ArticleId>
            <ArticleId IdType="pubmed">24373847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, et al.  (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene
35: 4191–4199. 10.1038/onc.2015.483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC, Van Seuningen I, Hollingsworth MA, Aubert JP, Batra SK (2007) MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene
26: 30–41. 10.1038/sj.onc.1209764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209764</ArticleId>
            <ArticleId IdType="pubmed">16799633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, et al.  (2013) CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene
32: 2282–2287. 10.1038/onc.2012.251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.251</ArticleId>
            <ArticleId IdType="pubmed">22797075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quaresma MC, Pankonien I, Clarke LA, Sousa LS, Silva IAL, Railean V, Doušová T, Fuxe J, Amaral MD (2020) Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition. Cell Death Dis
11: 920. 10.1038/s41419-020-03119-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03119-z</ArticleId>
            <ArticleId IdType="pmc">PMC7588414</ArticleId>
            <ArticleId IdType="pubmed">33106471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol
15: 178–196. 10.1038/nrm3758</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3758</ArticleId>
            <ArticleId IdType="pmc">PMC4240281</ArticleId>
            <ArticleId IdType="pubmed">24556840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT: 2016. Cell
166: 21–45. 10.1016/j.cell.2016.06.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.06.028</ArticleId>
            <ArticleId IdType="pubmed">27368099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, et al.  (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol
21: 341–352. 10.1038/s41580-020-0237-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-020-0237-9</ArticleId>
            <ArticleId IdType="pmc">PMC7250738</ArticleId>
            <ArticleId IdType="pubmed">32300252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral MD, Quaresma MC, Pankonien I (2020) What role does CFTR play in development, differentiation, regeneration and cancer?
Int J Mol Sci
21: 3133. 10.3390/ijms21093133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21093133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke LA, Botelho HM, Sousa L, Falcao AO, Amaral MD (2015) Transcriptome meta-analysis reveals common differential and global gene expression profiles in cystic fibrosis and other respiratory disorders and identifies CFTR regulators. Genomics
106: 268–277. 10.1016/j.ygeno.2015.07.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygeno.2015.07.005</ArticleId>
            <ArticleId IdType="pubmed">26225835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botelho HM, Uliyakina I, Awatade NT, Proença MC, Tischer C, Sirianant L, Kunzelmann K, Pepperkok R, Amaral MD (2015) Protein traffic disorders: An effective high-throughput fluorescence microscopy pipeline for drug discovery. Sci Rep
5: 9038. 10.1038/srep09038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep09038</ArticleId>
            <ArticleId IdType="pmc">PMC4356983</ArticleId>
            <ArticleId IdType="pubmed">25762484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, von Haller PD, et al.  (2008) New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal
1: ra12. 10.1126/scisignal.2000037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2000037</ArticleId>
            <ArticleId IdType="pubmed">19001663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell
130: 1120–1133. 10.1016/j.cell.2007.07.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al.  (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev
22: 1962–1971. 10.1101/gad.1664408</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1664408</ArticleId>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couzens AL, Knight JD, Kean MJ, Teo G, Weiss A, Dunham WH, Lin ZY, Bagshaw RD, Sicheri F, Pawson T, et al.  (2013) Protein interaction network of the mammalian hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal
6: rs15. 10.1126/scisignal.2004712</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004712</ArticleId>
            <ArticleId IdType="pubmed">24255178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauri S, Wepf A, Van Drogen A, Varjosalo M, Tapon N, Aebersold R, Gstaiger M (2013) Interaction proteome of human Hippo signaling: Modular control of the co-activator YAP1. Mol Syst Biol
9: 713–716. 10.1002/msb.201304750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/msb.201304750</ArticleId>
            <ArticleId IdType="pmc">PMC4019981</ArticleId>
            <ArticleId IdType="pubmed">24366813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Li X, Huang J, Feng L, Dolinta KG, Chen J (2014) Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics
13: 119–131. 10.1074/mcp.M113.030049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M113.030049</ArticleId>
            <ArticleId IdType="pmc">PMC3879608</ArticleId>
            <ArticleId IdType="pubmed">24126142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M, Balch WE, Yates JR (2015) ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature
528: 510–516. 10.1038/nature15729</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15729</ArticleId>
            <ArticleId IdType="pmc">PMC4826614</ArticleId>
            <ArticleId IdType="pubmed">26618866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al.  (2019) STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res
47: D607. 10.1093/nar/gky1131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Liu J, Ying X, Lin PC, Zhou BP (2016) Twist-mediated epithelial-mesenchymal transition promotes breast tumor cell invasion via inhibition of hippo pathway. Sci Rep
6: 24606. 10.1038/srep24606</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep24606</ArticleId>
            <ArticleId IdType="pmc">PMC4837350</ArticleId>
            <ArticleId IdType="pubmed">27094683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y, Liu Y, Zhang L, Lu Y, Shan H, et al.  (2019) YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ
26: 1832–1844. 10.1038/s41418-018-0250-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0250-0</ArticleId>
            <ArticleId IdType="pmc">PMC6748107</ArticleId>
            <ArticleId IdType="pubmed">30644438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Pan D (2019) The hippo signaling pathway in development and disease. Dev Cell
50: 264–282. 10.1016/j.devcel.2019.06.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2019.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC6748048</ArticleId>
            <ArticleId IdType="pubmed">31386861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey A, Varelas X, Guan KL (2020) Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov
19: 480–494. 10.1038/s41573-020-0070-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-020-0070-z</ArticleId>
            <ArticleId IdType="pmc">PMC7880238</ArticleId>
            <ArticleId IdType="pubmed">32555376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farinha CM, Matos P (2016) Repairing the basic defect in cystic fibrosis - one approach is not enough. FEBS J
283: 246–264. 10.1111/febs.13531</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.13531</ArticleId>
            <ArticleId IdType="pubmed">26416076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell
29: 783–803. 10.1016/j.ccell.2016.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reilly R, Mroz MS, Dempsey E, Wynne K, Keely SJ, McKone EF, Hiebel C, Behl C, Coppinger JA (2017) Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Sci Rep
7: 7642. 10.1038/s41598-017-06588-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-06588-z</ArticleId>
            <ArticleId IdType="pmc">PMC5550428</ArticleId>
            <ArticleId IdType="pubmed">28794469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL (2011) Plasma TGF-β₁ in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy. Pediatr Pulmonol
46: 688–695. 10.1002/ppul.21430</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ppul.21430</ArticleId>
            <ArticleId IdType="pmc">PMC3115503</ArticleId>
            <ArticleId IdType="pubmed">21337732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris WT, Kelly DR, Zhou Y, Wang D, Macewen M, Macewen M, Hagood JS, Clancy JP, Ambalavanan N, Sorscher EJ (2013) Myofibroblast differentiation and enhanced Tgf-B signaling in cystic fibrosis lung disease. PLoS One
8: e70196. 10.1371/journal.pone.0070196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0070196</ArticleId>
            <ArticleId IdType="pmc">PMC3741283</ArticleId>
            <ArticleId IdType="pubmed">23950911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Soldt BJ, Cardoso WV (2020) Hippo-Yap/Taz signaling: Complex network interactions and impact in epithelial cell behavior. Wiley Interdiscip Rev Dev Biol
9: e371. 10.1002/wdev.371</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wdev.371</ArticleId>
            <ArticleId IdType="pubmed">31828974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al.  (2011) Role of YAP/TAZ in mechanotransduction. Nature
474: 179–183. 10.1038/nature10137</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10137</ArticleId>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al.  (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev
21: 2747–2761. 10.1101/gad.1602907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1602907</ArticleId>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeSimple P, Liao J, Robert R, Gruenert DC, Hanrahan JW (2010) Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers. J Physiol
588: 1195–1209. 10.1113/jphysiol.2009.182246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2009.182246</ArticleId>
            <ArticleId IdType="pmc">PMC2872727</ArticleId>
            <ArticleId IdType="pubmed">20156845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankonien I, Quaresma MC, Rodrigues CS, Amaral MD (2022) CFTR, cell junctions and the cytoskeleton. Int J Mol Sci
23: 2688. 10.3390/ijms23052688</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms23052688</ArticleId>
            <ArticleId IdType="pmc">PMC8910340</ArticleId>
            <ArticleId IdType="pubmed">35269829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, et al.  (2018) Oncogenic signaling pathways in the cancer genome atlas. Cell
173: 321–337.e10. 10.1016/j.cell.2018.03.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC6070353</ArticleId>
            <ArticleId IdType="pubmed">29625050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao YH, Lafita-Navarro MC, Zacharias L, Borenstein-Auerbach N, Kim M, Barnes S, Kim J, Shay J, Deberardinis RJ, Conacci-Sorrell M (2019) Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation. Cell Commun Signal
17: 129. 10.1186/s12964-019-0444-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-019-0444-1</ArticleId>
            <ArticleId IdType="pmc">PMC6798382</ArticleId>
            <ArticleId IdType="pubmed">31623618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Zhu J, Shi B, Wang X, Lu Q, Li C, Chen H (2019) The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res
38: 304–316. 10.1186/s13046-019-1296-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1296-7</ArticleId>
            <ArticleId IdType="pmc">PMC6625065</ArticleId>
            <ArticleId IdType="pubmed">31296250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piersma B, Bank RA, Boersema M (2015) Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med (Lausanne)
2: 59. 10.3389/fmed.2015.00059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2015.00059</ArticleId>
            <ArticleId IdType="pmc">PMC4558529</ArticleId>
            <ArticleId IdType="pubmed">26389119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raj N, Bam R (2019) Reciprocal crosstalk between YAP1/hippo pathway and the p53 family proteins: Mechanisms and outcomes in cancer. Front Cell Dev Biol
7: 159. 10.3389/fcell.2019.00159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00159</ArticleId>
            <ArticleId IdType="pmc">PMC6695833</ArticleId>
            <ArticleId IdType="pubmed">31448276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croci O, De Fazio S, Biagioni F, Donato E, Caganova M, Curti L, Doni M, Sberna S, Aldeghi D, Biancotto C, et al.  (2017) Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. Genes Dev
31: 2017–2022. 10.1101/gad.301184.117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.301184.117</ArticleId>
            <ArticleId IdType="pmc">PMC5733494</ArticleId>
            <ArticleId IdType="pubmed">29141911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, et al.  (2018) MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia. Am J Respir Crit Care Med
197: 632–643. 10.1164/rccm.201704-0732OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201704-0732OC</ArticleId>
            <ArticleId IdType="pmc">PMC6005236</ArticleId>
            <ArticleId IdType="pubmed">29232160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicola T, Kabir FL, Coric T, Wall SB, Zhang W, James M, MacEwen M, Ren C, Halloran B, Ambalavanan N, et al.  (2019) CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia. Physiol Rep
7: e13977. 10.14814/phy2.13977</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14814/phy2.13977</ArticleId>
            <ArticleId IdType="pmc">PMC6389738</ArticleId>
            <ArticleId IdType="pubmed">30806029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JT, Wang Y, Chen JJ, Zhang XH, Dong JD, Tsang LL, Huang XR, Cai Z, Lan HY, Jiang XH, et al.  (2017) Defective CFTR leads to aberrant β-catenin activation and kidney fibrosis. Sci Rep
7: 5233. 10.1038/s41598-017-05435-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-05435-5</ArticleId>
            <ArticleId IdType="pmc">PMC5507915</ArticleId>
            <ArticleId IdType="pubmed">28701694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness ST, Clarke LL (2018) Cftr modulates wnt/β-catenin signaling and stem cell proliferation in murine intestine. Cell Mol Gastroenterol Hepatol
5: 253–271. 10.1016/j.jcmgh.2017.11.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2017.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC5904038</ArticleId>
            <ArticleId IdType="pubmed">29675451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vrbanac V, Probst CK, Hiemer SE, Sisson TH, Horowitz JC, et al.  (2015) Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol
308: L344–L357. 10.1152/ajplung.00300.2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00300.2014</ArticleId>
            <ArticleId IdType="pmc">PMC4329470</ArticleId>
            <ArticleId IdType="pubmed">25502501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marquard S, Thomann S, Weiler SME, Bissinger M, Lutz T, Sticht C, Tóth M, de la Torre C, Gretz N, Straub BK, et al.  (2020) Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Commun Signal
18: 166. 10.1186/s12964-020-00634-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-020-00634-6</ArticleId>
            <ArticleId IdType="pmc">PMC7583285</ArticleId>
            <ArticleId IdType="pubmed">33097058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Tan R, Dai C, Li Y, Wang D, Hao S, Kahn M, Liu Y (2010) Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem
285: 24665–24675. 10.1074/jbc.M109.091256</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.091256</ArticleId>
            <ArticleId IdType="pmc">PMC2915703</ArticleId>
            <ArticleId IdType="pubmed">20519507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omori K, Hattori N, Senoo T, Takayama Y, Masuda T, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Kohno N (2016) Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS One
11: e0148969. 10.1371/journal.pone.0148969</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0148969</ArticleId>
            <ArticleId IdType="pmc">PMC4747467</ArticleId>
            <ArticleId IdType="pubmed">26859294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kortlever RM, Higgins PJ, Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol
8: 877–884. 10.1038/ncb1448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1448</ArticleId>
            <ArticleId IdType="pmc">PMC2954492</ArticleId>
            <ArticleId IdType="pubmed">16862142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2019) The TGF-β1/p53/PAI-1 signaling axis in vascular senescence: Role of caveolin-1. Biomolecules
9: 1–12. 10.3390/biom9080341</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom9080341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rausch V, Bostrom JR, Park J, Bravo IR, Feng Y, Hay DC, Link BA, Hansen CG (2019) The hippo pathway regulates caveolae expression and mediates flow response via caveolae. Curr Biol
29: 242–255.e6. 10.1016/j.cub.2018.11.066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2018.11.066</ArticleId>
            <ArticleId IdType="pmc">PMC6345631</ArticleId>
            <ArticleId IdType="pubmed">30595521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Vicente R, Pavón DM, Martín-Padura I, Català-Montoro M, Díez-Sánchez A, Quílez-Álvarez A, López JA, Sánchez-Álvarez M, Vázquez J, Strippoli R, et al.  (2018) Caveolin-1 modulates mechanotransduction responses to substrate stiffness through actin-dependent control of YAP. Cell Rep
25: 1622–1635.e6. 10.1016/j.celrep.2018.10.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.10.024</ArticleId>
            <ArticleId IdType="pmc">PMC6231326</ArticleId>
            <ArticleId IdType="pubmed">30404014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, et al.  (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res
10: 218–229. 10.1158/1541-7786.MCR-11-0451</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-11-0451</ArticleId>
            <ArticleId IdType="pmc">PMC3908884</ArticleId>
            <ArticleId IdType="pubmed">22144662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Krause A, Hamai H, Harvey BG, Worgall TS, Worgall S (2010) Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS One
5: e11004. 10.1371/journal.pone.0011004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011004</ArticleId>
            <ArticleId IdType="pmc">PMC2882373</ArticleId>
            <ArticleId IdType="pubmed">20543983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haase M, Fitze G (2016) HSP90AB1: Helping the good and the bad. Gene
575: 171–186. 10.1016/j.gene.2015.08.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2015.08.063</ArticleId>
            <ArticleId IdType="pmc">PMC5675009</ArticleId>
            <ArticleId IdType="pubmed">26358502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J, Liu H, Wang S, Li G (2019) Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression. Oncogene
38: 1489–1507. 10.1038/s41388-018-0532-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0532-5</ArticleId>
            <ArticleId IdType="pmc">PMC6372478</ArticleId>
            <ArticleId IdType="pubmed">30305727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia L, Ge X, Du C, Chen L, Zhou Y, Xiong W, Xiang J, Li G, Xiao G, Fang L, et al.  (2021) EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling. Br J Cancer
124: 1301–1311. 10.1038/s41416-020-01250-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-01250-4</ArticleId>
            <ArticleId IdType="pmc">PMC8007567</ArticleId>
            <ArticleId IdType="pubmed">33473168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kochhar A, Kopelovich L, Sue E, Guttenplan JB, Herbert BS, Dannenberg AJ, Subbaramaiah K (2014) p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling. Cancer Prev Res (Phila)
7: 596–606. 10.1158/1940-6207.CAPR-14-0051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-14-0051</ArticleId>
            <ArticleId IdType="pmc">PMC4074578</ArticleId>
            <ArticleId IdType="pubmed">24736433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, et al.  (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell
127: 803–815. 10.1016/j.cell.2006.09.043</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.09.043</ArticleId>
            <ArticleId IdType="pubmed">17110338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Wu Z, Zhang J, Zhou R, Ye L, Yang P, Yu B (2020) Development and validation of an oxidative phosphorylation-related gene signature in lung adenocarcinoma. Epigenomics
12: 1333–1348. 10.2217/epi-2020-0217</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/epi-2020-0217</ArticleId>
            <ArticleId IdType="pubmed">32787683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He TL, Zhang YJ, Jiang H, Li XH, Zhu H, Zheng KL (2015) The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med Oncol
32: 187–188. 10.1007/s12032-015-0633-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-015-0633-8</ArticleId>
            <ArticleId IdType="pmc">PMC4452209</ArticleId>
            <ArticleId IdType="pubmed">26021472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Li P, Wang J, Liu J (2020) STIP1 down-regulation inhibits glycolysis by suppressing PKM2 and LDHA and inactivating the Wnt/β-catenin pathway in cervical carcinoma cells. Life Sci
258: 118190. 10.1016/j.lfs.2020.118190</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.118190</ArticleId>
            <ArticleId IdType="pubmed">32777299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantiello HF (2001) Role of actin filament organization in CFTR activation. Pflugers Arch
443: S75–S80. 10.1007/s004240100649</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004240100649</ArticleId>
            <ArticleId IdType="pubmed">11845308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baczynska D, Bombik I, Malicka-Błaszkiewicz M (2016) β-Catenin expression regulates cell migration of human colonic adenocarcinoma cells through gelsolin. Anticancer Res
36: 5249–5256. 10.21873/anticanres.11095</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.11095</ArticleId>
            <ArticleId IdType="pubmed">27798885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An JH, Kim JW, Jang SM, Kim CH, Kang EJ, Choi KH (2011) Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun
412: 44–49. 10.1016/j.bbrc.2011.07.034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2011.07.034</ArticleId>
            <ArticleId IdType="pubmed">21801713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirkos S, Newbigging S, Nguyen V, Keet M, Ackerley C, Kent G, Rozmahel RF (2006) Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respir Res
7: 51. 10.1186/1465-9921-7-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1465-9921-7-51</ArticleId>
            <ArticleId IdType="pmc">PMC1456967</ArticleId>
            <ArticleId IdType="pubmed">16571124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan L, Wu R, Ye L, Wang H, Yang X, Zhang Y, Chen X, Zuo G, Zhang Y, Weng Y, et al.  (2013) S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/β-catenin pathway. PLoS One
8: e62092. 10.1371/journal.pone.0062092</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0062092</ArticleId>
            <ArticleId IdType="pmc">PMC3637369</ArticleId>
            <ArticleId IdType="pubmed">23637971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Kong F, Jin C, Hu E, Shao Q, Liu J, He D, Xiao X (2019) The expression of S100A8/S100A9 is inducible and regulated by the Hippo/YAP pathway in squamous cell carcinomas. BMC Cancer
19: 597. 10.1186/s12885-019-5784-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5784-0</ArticleId>
            <ArticleId IdType="pmc">PMC6580480</ArticleId>
            <ArticleId IdType="pubmed">31208368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farinha CM, Amaral MD (2005) Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol
25: 5242–5252. 10.1128/MCB.25.12.5242-5252.2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.25.12.5242-5252.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1140594</ArticleId>
            <ArticleId IdType="pubmed">15923638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, Sorscher EJ, Clancy JP (2005) Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol
569: 601–615. 10.1113/jphysiol.2005.096669</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2005.096669</ArticleId>
            <ArticleId IdType="pmc">PMC1464253</ArticleId>
            <ArticleId IdType="pubmed">16210354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erfle H, Neumann B, Liebel U, Rogers P, Held M, Walter T, Ellenberg J, Pepperkok R (2007) Reverse transfection on cell arrays for high content screening microscopy. Nat Protoc
2: 392–399. 10.1038/nprot.2006.483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2006.483</ArticleId>
            <ArticleId IdType="pubmed">17406600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemeijer MC, Vonk AM, Awatade NT, Silva IAL, Tischer C, Hilsenstein V, Beekman JM, Amaral MD, Botelho HM (2020) An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay. Bioinformatics
36: 5686–5694. 10.1093/bioinformatics/btaa1073</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btaa1073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al.  (2012) Fiji: An open-source platform for biological-image analysis. Nat Methods
9: 676–682. 10.1038/nmeth.2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId>
            <ArticleId IdType="pmc">PMC3855844</ArticleId>
            <ArticleId IdType="pubmed">22743772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi H, Ebert D, Muruganujan A, Mills C, Albou LP, Mushayamaha T, Thomas PD (2021) PANTHER version 16: A revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res
49: D394–D403. 10.1093/nar/gkaa1106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa1106</ArticleId>
            <ArticleId IdType="pmc">PMC7778891</ArticleId>
            <ArticleId IdType="pubmed">33290554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.  (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A
102: 15545–15550. 10.1073/pnas.0506580102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wickham H (2016) ggplot2: Elegant graphics for data analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)
174. 10.1007/978-3-319-24277-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-24277-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Boutros PC (2011) VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics
12: 35. 10.1186/1471-2105-12-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-12-35</ArticleId>
            <ArticleId IdType="pmc">PMC3041657</ArticleId>
            <ArticleId IdType="pubmed">21269502</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35500936</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2575-1077</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Life science alliance</Title>
          <ISOAbbreviation>Life Sci Alliance</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Exploring YAP1-centered networks linking dysfunctional CFTR to epithelial-mesenchymal transition.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e202101326</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.26508/lsa.202101326</ELocationID>
        <Abstract>
          <AbstractText>Mutations in the CFTR anion channel cause cystic fibrosis (CF) and have also been related to higher cancer incidence. Previously we proposed that this is linked to an emerging role of functional CFTR in protecting against epithelial-mesenchymal transition (EMT). However, the pathways bridging dysfunctional CFTR to EMT remain elusive. Here, we applied systems biology to address this question. Our data show that YAP1 is aberrantly active in the presence of mutant CFTR, interacting with F508del, but not with wt-CFTR, and that YAP1 knockdown rescues F508del-CFTR processing and function. Subsequent analysis of YAP1 interactors and roles in cells expressing either wt- or F508del-CFTR reveal that YAP1 is an important mediator of the fibrotic/EMT processes in CF. Alongside, five main pathways emerge here as key in linking mutant CFTR to EMT, namely, (1) the Hippo pathway; (2) the Wnt pathway; (3) the TGFβ pathway; (4) the p53 pathway; and (5) MYC signaling. Several potential hub proteins which mediate the crosstalk among these pathways were also identified, appearing as potential therapeutic targets for both CF and cancer.</AbstractText>
          <CopyrightInformation>© 2022 Quaresma et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Quaresma</LastName>
            <ForeName>Margarida C</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Botelho</LastName>
            <ForeName>Hugo M</ForeName>
            <Initials>HM</Initials>
            <Identifier Source="ORCID">0000-0002-4208-1086</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pankonien</LastName>
            <ForeName>Ines</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4622-7521</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rodrigues</LastName>
            <ForeName>Cláudia S</ForeName>
            <Initials>CS</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinto</LastName>
            <ForeName>Madalena C</ForeName>
            <Initials>MC</Initials>
            <Identifier Source="ORCID">0000-0001-9045-269X</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Costa</LastName>
            <ForeName>Pau R</ForeName>
            <Initials>PR</Initials>
            <Identifier Source="ORCID">0000-0003-3527-5381</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Duarte</LastName>
            <ForeName>Aires</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Amaral</LastName>
            <ForeName>Margarida D</ForeName>
            <Initials>MD</Initials>
            <Identifier Source="ORCID">0000-0002-0828-8630</Identifier>
            <AffiliationInfo>
              <Affiliation>BioISI-Biosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Lisboa, Portugal mdamaral@fc.ul.pt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Life Sci Alliance</MedlineTA>
        <NlmUniqueID>101728869</NlmUniqueID>
        <ISSNLinking>2575-1077</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C505032">CFTR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016271">Proto-Oncogene Proteins c-myc</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000091102">YAP-Signaling Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088374">YAP1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>126880-72-6</RegistryNumber>
          <NameOfSubstance UI="D019005">Cystic Fibrosis Transmembrane Conductance Regulator</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019005" MajorTopicYN="Y">Cystic Fibrosis Transmembrane Conductance Regulator</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016271" MajorTopicYN="N">Proto-Oncogene Proteins c-myc</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000091102" MajorTopicYN="N">YAP-Signaling Proteins</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>20</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35500936</ArticleId>
        <ArticleId IdType="pmc">PMC9060002</ArticleId>
        <ArticleId IdType="doi">10.26508/lsa.202101326</ArticleId>
        <ArticleId IdType="pii">5/9/e202101326</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science
245: 1066–1073. 10.1126/science.2475911</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2475911</ArticleId>
            <ArticleId IdType="pubmed">2475911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet
373: 1891–1904. 10.1016/S0140-6736(09)60327-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(09)60327-5</ArticleId>
            <ArticleId IdType="pubmed">19403164</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Boeck K, Amaral MD (2016) Progress in therapies for cystic fibrosis. Lancet Respir Med
4: 662–674. 10.1016/S2213-2600(16)00023-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(16)00023-0</ArticleId>
            <ArticleId IdType="pubmed">27053340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell SC, De Boeck K, Amaral MD (2015) New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol Ther
145: 19–34. 10.1016/j.pharmthera.2014.06.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pharmthera.2014.06.005</ArticleId>
            <ArticleId IdType="pubmed">24932877</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisonneuve P, Marshall BC, Knapp EA, Lowenfels AB (2013) Cancer risk in cystic fibrosis: A 20-year nationwide study from the United States. J Natl Cancer Inst
105: 122–129. 10.1093/jnci/djs481</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djs481</ArticleId>
            <ArticleId IdType="pubmed">23178438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller AC, Comellas AP, Hornick DB, Stoltz DA, Cavanaugh JE, Gerke AK, Welsh MJ, Zabner J, Polgreen PM (2020) Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A
117: 1621–1627. 10.1073/pnas.1914912117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1914912117</ArticleId>
            <ArticleId IdType="pmc">PMC6983448</ArticleId>
            <ArticleId IdType="pubmed">31882447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JT, Jiang XH, Xie C, Cheng H, Da Dong J, Wang Y, Fok KL, Zhang XH, Sun TT, Tsang LL, et al.  (2013) Downregulation of CFTR promotes epithelial-to-mesenchymal transition and is associated with poor prognosis of breast cancer. Biochim Biophys Acta
1833: 2961–2969. 10.1016/j.bbamcr.2013.07.021</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2013.07.021</ArticleId>
            <ArticleId IdType="pubmed">23916755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tu Z, Chen Q, Zhang JT, Jiang X, Xia Y, Chan HC (2016) CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis. Oncotarget
7: 76955–76965. 10.18632/oncotarget.12762</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.12762</ArticleId>
            <ArticleId IdType="pmc">PMC5363562</ArticleId>
            <ArticleId IdType="pubmed">27769067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Zhang JT, Jiang X, Shi X, Shen J, Feng F, Chen J, Liu G, He P, Jiang J, et al.  (2015) The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer. Int J Oncol
46: 2107–2115. 10.3892/ijo.2015.2921</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijo.2015.2921</ArticleId>
            <ArticleId IdType="pubmed">25760446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun TT, Wang Y, Cheng H, Xiao HZ, Xiang JJ, Zhang JT, Yu SB, Martin TA, Ye L, Tsang LL, et al.  (2014) Disrupted interaction between CFTR and AF-6/afadin aggravates malignant phenotypes of colon cancer. Biochim Biophys Acta
1843: 618–628. 10.1016/j.bbamcr.2013.12.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2013.12.013</ArticleId>
            <ArticleId IdType="pubmed">24373847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Than BLN, Linnekamp JF, Starr TK, Largaespada DA, Rod A, Zhang Y, Bruner V, Abrahante J, Schumann A, Luczak T, et al.  (2016) CFTR is a tumor suppressor gene in murine and human intestinal cancer. Oncogene
35: 4191–4199. 10.1038/onc.2015.483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2015.483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh AP, Chauhan SC, Andrianifahanana M, Moniaux N, Meza JL, Copin MC, Van Seuningen I, Hollingsworth MA, Aubert JP, Batra SK (2007) MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms. Oncogene
26: 30–41. 10.1038/sj.onc.1209764</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1209764</ArticleId>
            <ArticleId IdType="pubmed">16799633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie C, Jiang XH, Zhang JT, Sun TT, Dong JD, Sanders AJ, Diao RY, Wang Y, Fok KL, Tsang LL, et al.  (2013) CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer. Oncogene
32: 2282–2287. 10.1038/onc.2012.251</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2012.251</ArticleId>
            <ArticleId IdType="pubmed">22797075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quaresma MC, Pankonien I, Clarke LA, Sousa LS, Silva IAL, Railean V, Doušová T, Fuxe J, Amaral MD (2020) Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition. Cell Death Dis
11: 920. 10.1038/s41419-020-03119-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-03119-z</ArticleId>
            <ArticleId IdType="pmc">PMC7588414</ArticleId>
            <ArticleId IdType="pubmed">33106471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol
15: 178–196. 10.1038/nrm3758</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm3758</ArticleId>
            <ArticleId IdType="pmc">PMC4240281</ArticleId>
            <ArticleId IdType="pubmed">24556840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieto MA, Huang RY, Jackson RA, Thiery JP (2016) EMT: 2016. Cell
166: 21–45. 10.1016/j.cell.2016.06.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.06.028</ArticleId>
            <ArticleId IdType="pubmed">27368099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, et al.  (2020) Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol
21: 341–352. 10.1038/s41580-020-0237-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-020-0237-9</ArticleId>
            <ArticleId IdType="pmc">PMC7250738</ArticleId>
            <ArticleId IdType="pubmed">32300252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amaral MD, Quaresma MC, Pankonien I (2020) What role does CFTR play in development, differentiation, regeneration and cancer?
Int J Mol Sci
21: 3133. 10.3390/ijms21093133</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21093133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clarke LA, Botelho HM, Sousa L, Falcao AO, Amaral MD (2015) Transcriptome meta-analysis reveals common differential and global gene expression profiles in cystic fibrosis and other respiratory disorders and identifies CFTR regulators. Genomics
106: 268–277. 10.1016/j.ygeno.2015.07.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ygeno.2015.07.005</ArticleId>
            <ArticleId IdType="pubmed">26225835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Botelho HM, Uliyakina I, Awatade NT, Proença MC, Tischer C, Sirianant L, Kunzelmann K, Pepperkok R, Amaral MD (2015) Protein traffic disorders: An effective high-throughput fluorescence microscopy pipeline for drug discovery. Sci Rep
5: 9038. 10.1038/srep09038</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep09038</ArticleId>
            <ArticleId IdType="pmc">PMC4356983</ArticleId>
            <ArticleId IdType="pubmed">25762484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Major MB, Roberts BS, Berndt JD, Marine S, Anastas J, Chung N, Ferrer M, Yi X, Stoick-Cooper CL, von Haller PD, et al.  (2008) New regulators of Wnt/beta-catenin signaling revealed by integrative molecular screening. Sci Signal
1: ra12. 10.1126/scisignal.2000037</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2000037</ArticleId>
            <ArticleId IdType="pubmed">19001663</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell
130: 1120–1133. 10.1016/j.cell.2007.07.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2007.07.019</ArticleId>
            <ArticleId IdType="pmc">PMC2666353</ArticleId>
            <ArticleId IdType="pubmed">17889654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al.  (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev
22: 1962–1971. 10.1101/gad.1664408</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1664408</ArticleId>
            <ArticleId IdType="pmc">PMC2492741</ArticleId>
            <ArticleId IdType="pubmed">18579750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Couzens AL, Knight JD, Kean MJ, Teo G, Weiss A, Dunham WH, Lin ZY, Bagshaw RD, Sicheri F, Pawson T, et al.  (2013) Protein interaction network of the mammalian hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal
6: rs15. 10.1126/scisignal.2004712</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2004712</ArticleId>
            <ArticleId IdType="pubmed">24255178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hauri S, Wepf A, Van Drogen A, Varjosalo M, Tapon N, Aebersold R, Gstaiger M (2013) Interaction proteome of human Hippo signaling: Modular control of the co-activator YAP1. Mol Syst Biol
9: 713–716. 10.1002/msb.201304750</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/msb.201304750</ArticleId>
            <ArticleId IdType="pmc">PMC4019981</ArticleId>
            <ArticleId IdType="pubmed">24366813</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, Li X, Huang J, Feng L, Dolinta KG, Chen J (2014) Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics
13: 119–131. 10.1074/mcp.M113.030049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.M113.030049</ArticleId>
            <ArticleId IdType="pmc">PMC3879608</ArticleId>
            <ArticleId IdType="pubmed">24126142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankow S, Bamberger C, Calzolari D, Martínez-Bartolomé S, Lavallée-Adam M, Balch WE, Yates JR (2015) ∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis. Nature
528: 510–516. 10.1038/nature15729</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature15729</ArticleId>
            <ArticleId IdType="pmc">PMC4826614</ArticleId>
            <ArticleId IdType="pubmed">26618866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al.  (2019) STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res
47: D607. 10.1093/nar/gky1131</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky1131</ArticleId>
            <ArticleId IdType="pmc">PMC6323986</ArticleId>
            <ArticleId IdType="pubmed">30476243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Liu J, Ying X, Lin PC, Zhou BP (2016) Twist-mediated epithelial-mesenchymal transition promotes breast tumor cell invasion via inhibition of hippo pathway. Sci Rep
6: 24606. 10.1038/srep24606</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep24606</ArticleId>
            <ArticleId IdType="pmc">PMC4837350</ArticleId>
            <ArticleId IdType="pubmed">27094683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Zhao X, Sun J, Su W, Zhang L, Li Y, Liu Y, Zhang L, Lu Y, Shan H, et al.  (2019) YAP1/Twist promotes fibroblast activation and lung fibrosis that conferred by miR-15a loss in IPF. Cell Death Differ
26: 1832–1844. 10.1038/s41418-018-0250-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0250-0</ArticleId>
            <ArticleId IdType="pmc">PMC6748107</ArticleId>
            <ArticleId IdType="pubmed">30644438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng Y, Pan D (2019) The hippo signaling pathway in development and disease. Dev Cell
50: 264–282. 10.1016/j.devcel.2019.06.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.devcel.2019.06.003</ArticleId>
            <ArticleId IdType="pmc">PMC6748048</ArticleId>
            <ArticleId IdType="pubmed">31386861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dey A, Varelas X, Guan KL (2020) Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov
19: 480–494. 10.1038/s41573-020-0070-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-020-0070-z</ArticleId>
            <ArticleId IdType="pmc">PMC7880238</ArticleId>
            <ArticleId IdType="pubmed">32555376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farinha CM, Matos P (2016) Repairing the basic defect in cystic fibrosis - one approach is not enough. FEBS J
283: 246–264. 10.1111/febs.13531</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.13531</ArticleId>
            <ArticleId IdType="pubmed">26416076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanconato F, Cordenonsi M, Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell
29: 783–803. 10.1016/j.ccell.2016.05.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2016.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC6186419</ArticleId>
            <ArticleId IdType="pubmed">27300434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reilly R, Mroz MS, Dempsey E, Wynne K, Keely SJ, McKone EF, Hiebel C, Behl C, Coppinger JA (2017) Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis. Sci Rep
7: 7642. 10.1038/s41598-017-06588-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-06588-z</ArticleId>
            <ArticleId IdType="pmc">PMC5550428</ArticleId>
            <ArticleId IdType="pubmed">28794469</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris WT, Muhlebach MS, Oster RA, Knowles MR, Clancy JP, Noah TL (2011) Plasma TGF-β₁ in pediatric cystic fibrosis: Potential biomarker of lung disease and response to therapy. Pediatr Pulmonol
46: 688–695. 10.1002/ppul.21430</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ppul.21430</ArticleId>
            <ArticleId IdType="pmc">PMC3115503</ArticleId>
            <ArticleId IdType="pubmed">21337732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harris WT, Kelly DR, Zhou Y, Wang D, Macewen M, Macewen M, Hagood JS, Clancy JP, Ambalavanan N, Sorscher EJ (2013) Myofibroblast differentiation and enhanced Tgf-B signaling in cystic fibrosis lung disease. PLoS One
8: e70196. 10.1371/journal.pone.0070196</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0070196</ArticleId>
            <ArticleId IdType="pmc">PMC3741283</ArticleId>
            <ArticleId IdType="pubmed">23950911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Soldt BJ, Cardoso WV (2020) Hippo-Yap/Taz signaling: Complex network interactions and impact in epithelial cell behavior. Wiley Interdiscip Rev Dev Biol
9: e371. 10.1002/wdev.371</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/wdev.371</ArticleId>
            <ArticleId IdType="pubmed">31828974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al.  (2011) Role of YAP/TAZ in mechanotransduction. Nature
474: 179–183. 10.1038/nature10137</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature10137</ArticleId>
            <ArticleId IdType="pubmed">21654799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al.  (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev
21: 2747–2761. 10.1101/gad.1602907</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1602907</ArticleId>
            <ArticleId IdType="pmc">PMC2045129</ArticleId>
            <ArticleId IdType="pubmed">17974916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LeSimple P, Liao J, Robert R, Gruenert DC, Hanrahan JW (2010) Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers. J Physiol
588: 1195–1209. 10.1113/jphysiol.2009.182246</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2009.182246</ArticleId>
            <ArticleId IdType="pmc">PMC2872727</ArticleId>
            <ArticleId IdType="pubmed">20156845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pankonien I, Quaresma MC, Rodrigues CS, Amaral MD (2022) CFTR, cell junctions and the cytoskeleton. Int J Mol Sci
23: 2688. 10.3390/ijms23052688</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms23052688</ArticleId>
            <ArticleId IdType="pmc">PMC8910340</ArticleId>
            <ArticleId IdType="pubmed">35269829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, et al.  (2018) Oncogenic signaling pathways in the cancer genome atlas. Cell
173: 321–337.e10. 10.1016/j.cell.2018.03.035</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2018.03.035</ArticleId>
            <ArticleId IdType="pmc">PMC6070353</ArticleId>
            <ArticleId IdType="pubmed">29625050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao YH, Lafita-Navarro MC, Zacharias L, Borenstein-Auerbach N, Kim M, Barnes S, Kim J, Shay J, Deberardinis RJ, Conacci-Sorrell M (2019) Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation. Cell Commun Signal
17: 129. 10.1186/s12964-019-0444-1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-019-0444-1</ArticleId>
            <ArticleId IdType="pmc">PMC6798382</ArticleId>
            <ArticleId IdType="pubmed">31623618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, Zhu J, Shi B, Wang X, Lu Q, Li C, Chen H (2019) The transcription factor LEF1 promotes tumorigenicity and activates the TGF-β signaling pathway in esophageal squamous cell carcinoma. J Exp Clin Cancer Res
38: 304–316. 10.1186/s13046-019-1296-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13046-019-1296-7</ArticleId>
            <ArticleId IdType="pmc">PMC6625065</ArticleId>
            <ArticleId IdType="pubmed">31296250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Piersma B, Bank RA, Boersema M (2015) Signaling in fibrosis: TGF-β, WNT, and YAP/TAZ converge. Front Med (Lausanne)
2: 59. 10.3389/fmed.2015.00059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2015.00059</ArticleId>
            <ArticleId IdType="pmc">PMC4558529</ArticleId>
            <ArticleId IdType="pubmed">26389119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raj N, Bam R (2019) Reciprocal crosstalk between YAP1/hippo pathway and the p53 family proteins: Mechanisms and outcomes in cancer. Front Cell Dev Biol
7: 159. 10.3389/fcell.2019.00159</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00159</ArticleId>
            <ArticleId IdType="pmc">PMC6695833</ArticleId>
            <ArticleId IdType="pubmed">31448276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Croci O, De Fazio S, Biagioni F, Donato E, Caganova M, Curti L, Doni M, Sberna S, Aldeghi D, Biancotto C, et al.  (2017) Transcriptional integration of mitogenic and mechanical signals by Myc and YAP. Genes Dev
31: 2017–2022. 10.1101/gad.301184.117</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.301184.117</ArticleId>
            <ArticleId IdType="pmc">PMC5733494</ArticleId>
            <ArticleId IdType="pubmed">29141911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lutful Kabir F, Ambalavanan N, Liu G, Li P, Solomon GM, Lal CV, Mazur M, Halloran B, Szul T, Gerthoffer WT, et al.  (2018) MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia. Am J Respir Crit Care Med
197: 632–643. 10.1164/rccm.201704-0732OC</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1164/rccm.201704-0732OC</ArticleId>
            <ArticleId IdType="pmc">PMC6005236</ArticleId>
            <ArticleId IdType="pubmed">29232160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicola T, Kabir FL, Coric T, Wall SB, Zhang W, James M, MacEwen M, Ren C, Halloran B, Ambalavanan N, et al.  (2019) CFTR dysfunction increases endoglin and TGF-β signaling in airway epithelia. Physiol Rep
7: e13977. 10.14814/phy2.13977</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14814/phy2.13977</ArticleId>
            <ArticleId IdType="pmc">PMC6389738</ArticleId>
            <ArticleId IdType="pubmed">30806029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JT, Wang Y, Chen JJ, Zhang XH, Dong JD, Tsang LL, Huang XR, Cai Z, Lan HY, Jiang XH, et al.  (2017) Defective CFTR leads to aberrant β-catenin activation and kidney fibrosis. Sci Rep
7: 5233. 10.1038/s41598-017-05435-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-05435-5</ArticleId>
            <ArticleId IdType="pmc">PMC5507915</ArticleId>
            <ArticleId IdType="pubmed">28701694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness ST, Clarke LL (2018) Cftr modulates wnt/β-catenin signaling and stem cell proliferation in murine intestine. Cell Mol Gastroenterol Hepatol
5: 253–271. 10.1016/j.jcmgh.2017.11.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmgh.2017.11.013</ArticleId>
            <ArticleId IdType="pmc">PMC5904038</ArticleId>
            <ArticleId IdType="pubmed">29675451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, Lagares D, Choi KM, Stopfer L, Marinković A, Vrbanac V, Probst CK, Hiemer SE, Sisson TH, Horowitz JC, et al.  (2015) Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am J Physiol Lung Cell Mol Physiol
308: L344–L357. 10.1152/ajplung.00300.2014</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajplung.00300.2014</ArticleId>
            <ArticleId IdType="pmc">PMC4329470</ArticleId>
            <ArticleId IdType="pubmed">25502501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marquard S, Thomann S, Weiler SME, Bissinger M, Lutz T, Sticht C, Tóth M, de la Torre C, Gretz N, Straub BK, et al.  (2020) Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Commun Signal
18: 166. 10.1186/s12964-020-00634-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12964-020-00634-6</ArticleId>
            <ArticleId IdType="pmc">PMC7583285</ArticleId>
            <ArticleId IdType="pubmed">33097058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He W, Tan R, Dai C, Li Y, Wang D, Hao S, Kahn M, Liu Y (2010) Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling. J Biol Chem
285: 24665–24675. 10.1074/jbc.M109.091256</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.091256</ArticleId>
            <ArticleId IdType="pmc">PMC2915703</ArticleId>
            <ArticleId IdType="pubmed">20519507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omori K, Hattori N, Senoo T, Takayama Y, Masuda T, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Kohno N (2016) Inhibition of plasminogen activator inhibitor-1 attenuates transforming growth factor-β-dependent epithelial mesenchymal transition and differentiation of fibroblasts to myofibroblasts. PLoS One
11: e0148969. 10.1371/journal.pone.0148969</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0148969</ArticleId>
            <ArticleId IdType="pmc">PMC4747467</ArticleId>
            <ArticleId IdType="pubmed">26859294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kortlever RM, Higgins PJ, Bernards R (2006) Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol
8: 877–884. 10.1038/ncb1448</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb1448</ArticleId>
            <ArticleId IdType="pmc">PMC2954492</ArticleId>
            <ArticleId IdType="pubmed">16862142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Samarakoon R, Higgins SP, Higgins CE, Higgins PJ (2019) The TGF-β1/p53/PAI-1 signaling axis in vascular senescence: Role of caveolin-1. Biomolecules
9: 1–12. 10.3390/biom9080341</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/biom9080341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rausch V, Bostrom JR, Park J, Bravo IR, Feng Y, Hay DC, Link BA, Hansen CG (2019) The hippo pathway regulates caveolae expression and mediates flow response via caveolae. Curr Biol
29: 242–255.e6. 10.1016/j.cub.2018.11.066</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2018.11.066</ArticleId>
            <ArticleId IdType="pmc">PMC6345631</ArticleId>
            <ArticleId IdType="pubmed">30595521</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moreno-Vicente R, Pavón DM, Martín-Padura I, Català-Montoro M, Díez-Sánchez A, Quílez-Álvarez A, López JA, Sánchez-Álvarez M, Vázquez J, Strippoli R, et al.  (2018) Caveolin-1 modulates mechanotransduction responses to substrate stiffness through actin-dependent control of YAP. Cell Rep
25: 1622–1635.e6. 10.1016/j.celrep.2018.10.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2018.10.024</ArticleId>
            <ArticleId IdType="pmc">PMC6231326</ArticleId>
            <ArticleId IdType="pubmed">30404014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G, Goltsov AA, Ren C, Kurosaka S, Edamura K, Logothetis R, DeMayo FJ, Troncoso P, Blando J, DiGiovanni J, et al.  (2012) Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer. Mol Cancer Res
10: 218–229. 10.1158/1541-7786.MCR-11-0451</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-11-0451</ArticleId>
            <ArticleId IdType="pmc">PMC3908884</ArticleId>
            <ArticleId IdType="pubmed">22144662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, Krause A, Hamai H, Harvey BG, Worgall TS, Worgall S (2010) Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA. PLoS One
5: e11004. 10.1371/journal.pone.0011004</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0011004</ArticleId>
            <ArticleId IdType="pmc">PMC2882373</ArticleId>
            <ArticleId IdType="pubmed">20543983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haase M, Fitze G (2016) HSP90AB1: Helping the good and the bad. Gene
575: 171–186. 10.1016/j.gene.2015.08.063</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2015.08.063</ArticleId>
            <ArticleId IdType="pmc">PMC5675009</ArticleId>
            <ArticleId IdType="pubmed">26358502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Deng G, Ai M, Xu Z, Mou T, Yu J, Liu H, Wang S, Li G (2019) Hsp90ab1 stabilizes LRP5 to promote epithelial-mesenchymal transition via activating of AKT and Wnt/β-catenin signaling pathways in gastric cancer progression. Oncogene
38: 1489–1507. 10.1038/s41388-018-0532-5</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0532-5</ArticleId>
            <ArticleId IdType="pmc">PMC6372478</ArticleId>
            <ArticleId IdType="pubmed">30305727</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia L, Ge X, Du C, Chen L, Zhou Y, Xiong W, Xiang J, Li G, Xiao G, Fang L, et al.  (2021) EEF1A2 interacts with HSP90AB1 to promote lung adenocarcinoma metastasis via enhancing TGF-β/SMAD signalling. Br J Cancer
124: 1301–1311. 10.1038/s41416-020-01250-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41416-020-01250-4</ArticleId>
            <ArticleId IdType="pmc">PMC8007567</ArticleId>
            <ArticleId IdType="pubmed">33473168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kochhar A, Kopelovich L, Sue E, Guttenplan JB, Herbert BS, Dannenberg AJ, Subbaramaiah K (2014) p53 modulates Hsp90 ATPase activity and regulates aryl hydrocarbon receptor signaling. Cancer Prev Res (Phila)
7: 596–606. 10.1158/1940-6207.CAPR-14-0051</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1940-6207.CAPR-14-0051</ArticleId>
            <ArticleId IdType="pmc">PMC4074578</ArticleId>
            <ArticleId IdType="pubmed">24736433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, et al.  (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell
127: 803–815. 10.1016/j.cell.2006.09.043</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.09.043</ArticleId>
            <ArticleId IdType="pubmed">17110338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Z, Wu Z, Zhang J, Zhou R, Ye L, Yang P, Yu B (2020) Development and validation of an oxidative phosphorylation-related gene signature in lung adenocarcinoma. Epigenomics
12: 1333–1348. 10.2217/epi-2020-0217</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/epi-2020-0217</ArticleId>
            <ArticleId IdType="pubmed">32787683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He TL, Zhang YJ, Jiang H, Li XH, Zhu H, Zheng KL (2015) The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer. Med Oncol
32: 187–188. 10.1007/s12032-015-0633-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12032-015-0633-8</ArticleId>
            <ArticleId IdType="pmc">PMC4452209</ArticleId>
            <ArticleId IdType="pubmed">26021472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Li P, Wang J, Liu J (2020) STIP1 down-regulation inhibits glycolysis by suppressing PKM2 and LDHA and inactivating the Wnt/β-catenin pathway in cervical carcinoma cells. Life Sci
258: 118190. 10.1016/j.lfs.2020.118190</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2020.118190</ArticleId>
            <ArticleId IdType="pubmed">32777299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantiello HF (2001) Role of actin filament organization in CFTR activation. Pflugers Arch
443: S75–S80. 10.1007/s004240100649</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004240100649</ArticleId>
            <ArticleId IdType="pubmed">11845308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baczynska D, Bombik I, Malicka-Błaszkiewicz M (2016) β-Catenin expression regulates cell migration of human colonic adenocarcinoma cells through gelsolin. Anticancer Res
36: 5249–5256. 10.21873/anticanres.11095</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21873/anticanres.11095</ArticleId>
            <ArticleId IdType="pubmed">27798885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An JH, Kim JW, Jang SM, Kim CH, Kang EJ, Choi KH (2011) Gelsolin negatively regulates the activity of tumor suppressor p53 through their physical interaction in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun
412: 44–49. 10.1016/j.bbrc.2011.07.034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2011.07.034</ArticleId>
            <ArticleId IdType="pubmed">21801713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tirkos S, Newbigging S, Nguyen V, Keet M, Ackerley C, Kent G, Rozmahel RF (2006) Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator. Respir Res
7: 51. 10.1186/1465-9921-7-51</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1465-9921-7-51</ArticleId>
            <ArticleId IdType="pmc">PMC1456967</ArticleId>
            <ArticleId IdType="pubmed">16571124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan L, Wu R, Ye L, Wang H, Yang X, Zhang Y, Chen X, Zuo G, Zhang Y, Weng Y, et al.  (2013) S100A8 and S100A9 are associated with colorectal carcinoma progression and contribute to colorectal carcinoma cell survival and migration via Wnt/β-catenin pathway. PLoS One
8: e62092. 10.1371/journal.pone.0062092</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0062092</ArticleId>
            <ArticleId IdType="pmc">PMC3637369</ArticleId>
            <ArticleId IdType="pubmed">23637971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Kong F, Jin C, Hu E, Shao Q, Liu J, He D, Xiao X (2019) The expression of S100A8/S100A9 is inducible and regulated by the Hippo/YAP pathway in squamous cell carcinomas. BMC Cancer
19: 597. 10.1186/s12885-019-5784-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12885-019-5784-0</ArticleId>
            <ArticleId IdType="pmc">PMC6580480</ArticleId>
            <ArticleId IdType="pubmed">31208368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farinha CM, Amaral MD (2005) Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol
25: 5242–5252. 10.1128/MCB.25.12.5242-5252.2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.25.12.5242-5252.2005</ArticleId>
            <ArticleId IdType="pmc">PMC1140594</ArticleId>
            <ArticleId IdType="pubmed">15923638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, Sorscher EJ, Clancy JP (2005) Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol
569: 601–615. 10.1113/jphysiol.2005.096669</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/jphysiol.2005.096669</ArticleId>
            <ArticleId IdType="pmc">PMC1464253</ArticleId>
            <ArticleId IdType="pubmed">16210354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Erfle H, Neumann B, Liebel U, Rogers P, Held M, Walter T, Ellenberg J, Pepperkok R (2007) Reverse transfection on cell arrays for high content screening microscopy. Nat Protoc
2: 392–399. 10.1038/nprot.2006.483</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nprot.2006.483</ArticleId>
            <ArticleId IdType="pubmed">17406600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hagemeijer MC, Vonk AM, Awatade NT, Silva IAL, Tischer C, Hilsenstein V, Beekman JM, Amaral MD, Botelho HM (2020) An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay. Bioinformatics
36: 5686–5694. 10.1093/bioinformatics/btaa1073</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btaa1073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al.  (2012) Fiji: An open-source platform for biological-image analysis. Nat Methods
9: 676–682. 10.1038/nmeth.2019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId>
            <ArticleId IdType="pmc">PMC3855844</ArticleId>
            <ArticleId IdType="pubmed">22743772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi H, Ebert D, Muruganujan A, Mills C, Albou LP, Mushayamaha T, Thomas PD (2021) PANTHER version 16: A revised family classification, tree-based classification tool, enhancer regions and extensive API. Nucleic Acids Res
49: D394–D403. 10.1093/nar/gkaa1106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa1106</ArticleId>
            <ArticleId IdType="pmc">PMC7778891</ArticleId>
            <ArticleId IdType="pubmed">33290554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.  (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A
102: 15545–15550. 10.1073/pnas.0506580102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0506580102</ArticleId>
            <ArticleId IdType="pmc">PMC1239896</ArticleId>
            <ArticleId IdType="pubmed">16199517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wickham H (2016) ggplot2: Elegant graphics for data analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)
174. 10.1007/978-3-319-24277-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-3-319-24277-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Boutros PC (2011) VennDiagram: A package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinformatics
12: 35. 10.1186/1471-2105-12-35</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2105-12-35</ArticleId>
            <ArticleId IdType="pmc">PMC3041657</ArticleId>
            <ArticleId IdType="pubmed">21269502</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
